

\*\*\*\*Published August 2022\*\*\*\*

## Vaccines Strategic Pipeline Review (CAT: VAMV084)

<b>Product Name</b>	:	<b>Vaccines Strategic Pipeline Review</b>
<b>Description</b>	:	Global vaccine R&D analysis – Industry only
<b>Contents</b>	:	Executive presentation (>75 slides.pdf) + 1 x MS-Excel Workbook (>1500 trials, >230 companies, 90 pathogens)
<b>Therapeutic Area</b>	:	<b>All vaccines (general)</b>
<b>Publication date</b>	:	August 2022
<b>Catalogue No</b>	:	VAMV084

## Background

Analysis of the current and historical **vaccine research and development (R&D) pipeline** is a critical component of any organisation's competitive intelligence effort. This exercise can inform both internal & external decision makers and input into many processes, including strategic portfolio management, business development and licensing, R&D prioritization and corporate development/investment. Key challenges with the analysis are that, not only is the vaccine pipeline dynamic, but a historical view requires skilled judgement during curation, especially when assigning new fields which can produce meaningful outputs.

This **Q3 2022 Vaccine Strategic Pipeline Review** (industry only) contains analysis of >1500 total clinical trials operated by >230 companies and investigates current and historical vaccine trial activity by inserting a range of new fields including: vaccine type/production system/adjuvant\*, infectious diseases, chronic conditions or cancer, pathogen/condition (~90 included), market segment, study duration and company size (Small, Medium and Large) and more. Using the **MS-Excel workbook database provided**, a range of tabular and graphical outputs help visualize competitive activity [current/past] and investment in various segments/pathogens relative to each other and the academic sector. These outputs form the basis of a gap analysis or heatmap that could guide future investment especially regarding new nucleic-based approaches.

A **mRNA vaccine landscape** focus section is now included with an emphasis on newly emerging **seasonal influenza** programs including mRNA-1010, mRNA-1020/30, mRNA-1073 (ModernaTX), PF-07252220, PF-07852352 (Pfizer)<sup>1</sup>, GSK4382276A (GSK) and SP0273 (Sanofi). Companies possessing mRNA technologies within the COVID-19 space are considered with possible acquisition targets identified.

<sup>1</sup> also PF-07836391, PF-07836394, PF-07836395, PF-07836396, PF-07867246

## Methodology

**VacZine Analytics** has closely monitored all significant source material pertaining to vaccine research & development activity. Source materials used are global clinical trial registries, literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by **VacZine Analytics** in the field of vaccines been used as a reference.

### PRODUCT CONTENTS:

**Published August 2022 (CAT No: VAMV084)**

\*\*\*\*This product is a [summary presentation \(.pdf\)](#), and a [MS Excel Workbook \(.xls\)](#)

### Contents – Summary presentation (.pdf)<sup>2</sup>

Contents  
Author's notes  
Executive summary  
Methodology 1)  
Methodology 2)  
Pathogens and conditions identified  
Market segment definitions  
Number of vaccine clinical trials identified  
Number of vaccine clinical trials: cancer vs non cancer  
Number of vaccine clinical trials: activity status  
Number of vaccine clinical trials: by Phase 1-4  
Number of vaccine clinical trials: per pathogen condition  
Number of vaccine clinical trials: per segment/activity  
Number of vaccine clinical trials: per company size  
Number of clinical trials per company size  
Large companies involved in vaccine clinical trials  
Medium companies involved in vaccine clinical trials  
Small companies involved in vaccine clinical trials  
Large companies: past/current clinical trials per market segment  
Large companies: past/current clinical trials per pathogen/condition  
Large companies: verified active programs by Phase, Q3 2022  
Large companies: verified active programs by segment, Q3 2022  
Large companies: verified active programs by pathogen, Q3 2022  
Proprietary analysis (*titles not disclosed*)  
Caveats and limitations of the analysis  
Bibliography  
About **VacZine Analytics**  
Disclaimer

**PAGES: >75 slides** fully referenced/sourced. Available in .pdf form

**Contents – MS Excel Workbook**  
**Worksheets = >40 interconnected**

<sup>2</sup> Full contents i.e., title per slide is proprietary and only available upon request

**PRODUCT COST:**

**VacZine Analytics** will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT (both deliverables) - USD **\$8,995.00**/ GBP **£7,495.00**# (Region license)\*

\*A region is North America, Europe or ROW

For orders in the UK, VAT at 20% will be added to the final invoice total

# - *indicative prevailing rate will be applied on date of transaction, third-party licenses may be restricted/vary*

**HOW TO ORDER:**

To order, please contact your region account manager or order direct at [orders@vaczine-analytics.com](mailto:orders@vaczine-analytics.com) This report can also be purchased online. Please review the **TERMS and CONDITIONS** of purchase.



**VacZine Analytics** © is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

**VacZine Analytics** © and the “spiral logo” are UK Registered Trademarks, 2009



## BIBLIOGRAPHY

References – only available upon valid request



**TERMS and CONDITIONS:**

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. All Rights Reserved. This finished research product is a licensed product. It may not be reproduced, stored in a retrieval system or transmitted in any form without the written permission of the Company **VacZine Analytics** (a division of Assay Advantage Ltd).
2. The license granted by the Company to the Client will be non-exclusive, non-transferable and should only be used for the Client business purposes at the agreed Client sites/location in accordance with this agreement. The Client will have no ownership rights over the research product.
3. Invoicing will **100%** after submission of the deliverables (.pdf) and (.xls) to the Client.
4. If not purchased online invoices are payable within **thirty days** of the invoice date.
5. All proposals are quoted in **\$USD dollars, or £GBP or €euro** and invoices are to be settled in the same currency.
6. The Company agrees not to disclose to any third-party confidential information acquired in the course of providing the research product listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees, and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
7. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
8. Please also refer to Master **TERMS and CONDITIONS** available upon request.

**VacZine Analytics**

A division of Assay Advantage Ltd  
Warren House  
Bells Hill  
Bishops Stortford  
Herts  
CM23 2NN  
United Kingdom  
Tel: +44 (0) 1279 927049 / Fax: +44 (0) 1279 927049  
E-mail: [info@vaczine-analytics.com](mailto:info@vaczine-analytics.com)

## About VacZine Analytics:

**VacZine Analytics** is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new monoclonals and biologics.

For more information, please visit our website [www.vacZine-analytics.com](http://www.vacZine-analytics.com)

**VacZine Analytics** © is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

**VacZine Analytics** © and "the spiral logo" are UK Registered Trademarks, 2009

